|
|
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) |
|
Price: $16.2400
$-0.09 
-0.551%
|
| Day's High:
| $16.24
| Week Perf:
| -4.86 %
|
| Day's Low: |
$ 16.24 |
30 Day Perf: |
-6.13 % |
| Volume (M): |
1 |
52 Wk High: |
$ 22.32 |
| Volume (M$): |
$ 12 |
52 Wk Avg: |
$13.84 |
| Open: |
$16.24 |
52 Wk Low: |
$6.20 |
|
|
| Market Capitalization (Millions $) |
21 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
30 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-16 |
| Cash Flow (TTM) (Millions $) |
-14 |
| Capital Exp. (TTM) (Millions $) |
0 |
Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Inc. is a biotechnology company based in the United States. The company focuses on the discovery and development of Anticalin-based drugs, which are therapeutic proteins derived from lipocalins, a type of human protein. Pieris Pharmaceuticals' drugs are designed to target specific diseases and bind to disease-causing proteins, offering potential treatments for a range of conditions including cancer, respiratory diseases, and metabolic disorders. The company aims to leverage its proprietary Anticalin platform to develop innovative therapies that address unmet medical needs.
Company Address: 225 Franklin Street, 26th Floor Boston 2110 MA
Company Phone Number: 246-8998 Stock Exchange / Ticker: NASDAQ PIRS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Inc, a leading biotechnology company, recently reported a disastrous financial performance for the span ending March 31, 2024. The company's revenue plummeted by a staggering 97.262% to $0.05 million, while the net loss per share expanded to $-3.95. This decline is in stark contrast to the corresponding financial reporting period a year ago when the net loss per share was $-0.04 and revenue experienced a decline of 95.92% from $1.30 million. Moreover, Pieris Pharmaceuticals Inc reported a net deficit of $-4.892 million compared to a deficit of $-13.183 million in the same period last year.
Struggling Financial Performance
Pieris Pharmaceuticals Inc's recent financial results reveal a gloomy outlook for the company. The significant decline in revenue is alarming and demonstrates troubling trends within its operations. This could indicate challenges in maintaining its product pipeline and securing new partnerships or collaborations. Furthermore, the drastic increase in net loss per share raises concerns about the company's ability to effectively manage its expenses and generate profitability.
|
| Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Inc, a major player in the pharmaceutical industry, has recently released its financial results for the October to December 31, 2023 period. The company has witnessed significant improvements in its earnings per share (EPS), with a decrease in loss per share compared to the same period last year. In fact, Pieris Pharmaceuticals Inc reported a loss per share of $-0.04, a notable improvement compared to the $-0.10 loss per share recorded a year ago.
Additionally, the revenue for the same period saw a sharp decline of -77.78%, falling to $1.30 million from $5.85 million in the previous financial span. Sequentially, there was an even more significant decrease of -93.345% in revenue, dropping from $19.52 million. This decline in revenue has impacted the company's financials, with a reported net loss of $-4.584 million for the defined period. However, it is worth highlighting that this loss is significantly lower than the deficit of $-8.102 million reported in the same period a year ago.
|
| Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Inc, a pharmaceutical company listed on the NASDAQ, has witnessed a decline of -8.45% in its stock value over the past seven days, resulting in a year-to-date performance of -77.83%. However, the company's latest financial results reveal robust revenue growth, increasing by 263.501% year on year to $19.52 million in the financial period ending on September 30, 2023. Despite this positive development, Pieris Pharmaceuticals Inc reported a net loss of $-0.11 per share for the same period. It is essential to analyze these results and consider their implications for the company's future prospects.
1. Strong Revenue Growth:
Pieris Pharmaceuticals Inc achieved a remarkable revenue increase of 263.501% compared to the previous year. This growth outperformed the Major Pharmaceutical Preparations industry, which experienced a 4.82% reduction in revenue during the same financial reporting period. The significant boost in revenue demonstrates the company's ability to attract customers and capitalize on market demand.
|
| Pieris Pharmaceuticals Inc
Despite Pieris Pharmaceuticals Inc's impressive revenue growth of 442.32% year on year, there are several concerning factors that suggest a bearish outlook for the company. While the company was able to achieve a positive EPS of $0.05 in the second quarter of 2023, this positive turnaround in earnings is unexpected given the drastic contraction of -9.44% in the Major Pharmaceutical Preparations industry.
Although Pieris Pharmaceuticals Inc's revenue doubled by 935.899% from $1.94 million to $20.06 million in the second quarter, it is important to note that this growth is relative to the preceding quarter and doesn't necessarily reflect long-term sustainability. Furthermore, the company's net margin increased to 19.83% and operating margin rose to 10.29%. While these improvements in profit margins may seem positive, the decline in accounts receivable to $1.0 million could indicate slowing demand for the company's products.
|
| Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has recorded a cumulative net loss of $-41 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on equity (ROE) of -133.94%. This is concerning news for investors, as it indicates that the company is not generating any profits and is losing money.
Furthermore, within the Major Pharmaceutical Preparations industry, 217 other companies had a higher return on equity than Pieris Pharmaceuticals Inc. This means that Pieris Pharmaceuticals Inc is falling behind its competitors in terms of generating profits.
|
| Per Share |
Current |
| Earnings (TTM) |
-11.87 $ |
| Revenues (TTM) |
1.02 $
|
| Cash Flow (TTM) |
- |
| Cash |
14.67 $
|
| Book Value |
12.32 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-11.87 $
|
| Revenues (TTM) |
1.02 $ |
| Cash Flow (TTM) |
- |
| Cash |
14.67 $
|
| Book Value |
12.32 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.08%